{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:06:05Z","timestamp":1793023565773,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202211379"],"award-info":[{"award-number":["tsqn202211379"]}],"id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972376"],"award-info":[{"award-number":["81972376"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2024MH001"],"award-info":[{"award-number":["ZR2024MH001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Chromophobe renal cell carcinoma (chRCC) is a rare subtype of renal cell carcinoma (RCC). Sarcomatoid differentiation is considered a result of dedifferentiation of the primary tumor. The coexistence of both components (chromophobe and sarcomatoid) in a single renal tumor has been infrequently reported. Currently, only isolated cases of metastatic sarcomatoid chRCC treated with immune checkpoint inhibitors (ICIs) or targeted therapies have been documented. Here, we present the first case of metastatic sarcomatoid chRCC treated with toripalimab plus axitinib and provide a review of the relevant literature. During a routine physical examination, a 58-year-old male was found to have a left renal mass. Subsequent imaging with computed tomography urography (CTU) revealed a 3.4 \u00d7 2.3 cm hypovascular tumor located in the middle pole of the left kidney, which was clinically diagnosed as left renal cell carcinoma. The patient underwent robotic-assisted laparoscopic left radical nephrectomy, and histological analysis confirmed the presence of chromophobe renal cell carcinoma with sarcomatoid differentiation. Unfortunately, twelve months post-surgery, the patient was diagnosed with retroperitoneal lymph node metastasis. Treatment with toripalimab (3mg\/kg, every 2weeks) plus axitinib (5 mg orally twice daily with a 12-hour interval) was initiated, and a significant response was observed after eight months. The treatment was well tolerated, with no significant adverse reactions, and the patient is currently continuing the treatment. Metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation is an extremely rare occurrence. The combination of toripalimab and axitinib may represent a promising treatment option for patients with chRCC and sarcomatoid differentiation.<\/jats:p>","DOI":"10.3389\/fonc.2025.1606414","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:10:27Z","timestamp":1754885427000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Significant response to toripalimab plus axitinib for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report and literature review"],"prefix":"10.3389","volume":"15","author":[{"given":"Xin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonglin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weicheng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunDong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.eururo.2014.04.029","article-title":"Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity","volume":"67","author":"Shuch","year":"2015","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.014","article-title":"The somatic\u00a0genomic landscape of chromophobe renal cell carcinoma","volume":"26","author":"Davis","year":"2014","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1464-410X.2011.10690.x","article-title":"Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicenter series","volume":"110","author":"Volpe","year":"2012","journal-title":"BJU Int"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.06.011","article-title":"Chromophobe renal cell carcinoma: results from a large single-institution series","volume":"17","author":"Casuscelli","year":"2019","journal-title":"Clin\u00a0Genitourin Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.03.018","article-title":"Metastatic chromophobe renal cell carcinoma: presence or absence of sarcomatoid differentiation determines clinical course and treatment outcomes","volume":"17","author":"Ged","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"Young","year":"2024","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.08.001","article-title":"Prognostic and therapeutic impact of the histopathologic definition of parenchymal epithelial renal tumors","volume":"58","author":"Ficarra","year":"2010","journal-title":"Eur Urol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: first global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.05.028","article-title":"Rapid response to nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma","volume":"15","author":"Rouvinov","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"B12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12894-018-0339-2","article-title":"Significant response to nivolumab for metastatic chromophobe renal\u00a0cell carcinoma with sarcomatoid differentiation: a case report","volume":"18","author":"Noguchi","year":"2018","journal-title":"BMC Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-022-00561-y","article-title":"Two case reports of immune checkpoint therapy on chromophobe renal cell carcinoma with sarcomatoid differentiation","volume":"11","author":"Fukushima","year":"2022","journal-title":"Int Canc Conf J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15586\/jkcvhl.v10i3.254","article-title":"Chromophobe renal cell carcinoma with sarcomatoid differentiation","volume":"10","author":"Lichtbroun","year":"2023","journal-title":"jkcvhl"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.049","article-title":"Everolimus versus sunitinib prospective evaluation in metastatic non\u2013clear cell renal cell carcinoma (ESPN): A randomized multicenter phase 2 trial","volume":"69","author":"Tannir","year":"2016","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00515-X","article-title":"Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicenter, open-label, randomized phase 2 trial","volume":"17","author":"Armstrong","year":"2016","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944","article-title":"Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates","volume":"40","author":"Lee","year":"2022","journal-title":"JCO"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02365","article-title":"Open-label, single-arm, phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non\u2013clear cell renal cell carcinoma","volume":"39","author":"McDermott","year":"2021","journal-title":"JCO"},{"key":"B19","doi-asserted-by":"publisher","first-page":"114350","DOI":"10.1016\/j.celrep.2024.114350","article-title":"Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma","volume":"43","author":"El Zarif","year":"2024","journal-title":"Cell Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"102374","DOI":"10.1016\/j.ctrv.2022.102374","article-title":"First-line immune checkpoint inhibitors in advanced or metastatic renal cell carcinoma with sarcomatoid features","volume":"105","author":"Fontes-Sousa","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.008","article-title":"Patients with sarcomatoid renal cell carcinoma \u2013 re-defining the first-line of treatment: A meta-analysis of randomized clinical trials with immune checkpoint inhibitors","author":"Iacovelli","year":"2020","journal-title":"Eur J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30937","article-title":"Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation","volume":"123","author":"Kawakami","year":"2017","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0269-x","article-title":"JAK2\/PD-L1\/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management","volume":"32","author":"Gupta","year":"2019","journal-title":"Modern Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2016.01.051","article-title":"Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations","volume":"70","author":"Malouf","year":"2016","journal-title":"Eur Urol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2011.06.005","article-title":"Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: A case report","volume":"9","author":"Matrana","year":"2011","journal-title":"Clin Genitourin Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1606414\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T04:10:28Z","timestamp":1754885428000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1606414\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":26,"alternative-id":["10.3389\/fonc.2025.1606414"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1606414","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"article-number":"1606414"}}